Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 8/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.55 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211213 | 0.91 | PTPN11 (0.64) | PTPN11S1PR3PTPN1PTPN6PLA2G4B | |
| SCHEMBL25788077 | 0.90 | PTPN11 (0.67) | PTPN11S1PR3PTPN1PTPN6PLA2G4B | |
| SCHEMBL2454085 | 0.90 | PPARG (0.56) | PTPN11S1PR3CYSLTR2CYSLTR1PLA2G4B | |
| SCHEMBL9417624 | 0.90 | PTPN11 (0.67) | PTPN11S1PR3PTPN1PTPN6PLA2G4B | |
| SCHEMBL16190196 | 0.88 | PTPN11 (0.59) | PTPN11S1PR3PTPN1PTPN6PLA2G4B | |
| SCHEMBL6381963 | 0.87 | KDM4E (0.54) | PTPN11S1PR3KDM4EPOLBPTPN1 | |
| SCHEMBL4304889 | 0.86 | PPARG (0.55) | PTPN11S1PR3KDM4EPOLBCYSLTR2 | |
| SCHEMBL25788087 | 0.86 | PTPN11 (0.60) | PTPN11S1PR3PTPN1PTPN6PLA2G4B | |
| SCHEMBL15728135 | 0.85 | PTPN11 (0.57) | PTPN11S1PR3KDM4EPOLBPLA2G4B | |
| SCHEMBL3903917 | 0.84 | KDM4E (0.60) | KDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | PTPN11 3041/4885S1PR3 871/4885KDM4E 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.